Acorda Signs Settlement With Mylan on Generic Ampyra
2018年8月3日 - 10:39PM
Dow Jones News
By Michael Dabaie
Biotechnology company Acorda Therapeutics Inc. (ACOR) on Friday
said it signed a conditioned settlement agreement with Mylan N.V.
(MYL) and affiliates over Acorda's multiple-sclerosis drug
Ampyra.
Under the settlement agreement, Mylan will be permitted to
market its generic version of Ampyra in the U.S. sometime in 2025
or earlier under certain circumstances, Acorda said in a filing
with the Securities and Exchange Commission.
Acorda also said it signed interim agreements with Teva
Pharmaceutical Industries Ltd. (TEVA) and Hikma Pharmaceuticals PLC
(HKMPY) concerning their patent litigation relating to Ampyra.
Acorda is awaiting a decision of the U.S. Court of Appeals for
the Federal Circuit in its appeal of a 2017 U.S. district court
decision that invalidated four of its Ampyra patents set to expire
between 2025 and 2027.
Acorda earlier this week reiterated it sees Ampyra 2018 net
revenue of $330 million to $350 million.
Write to Michael Dabaie at michael.dabaie@wsj.com
(END) Dow Jones Newswires
August 03, 2018 09:24 ET (13:24 GMT)
Copyright (c) 2018 Dow Jones & Company, Inc.
Teva Pharmaceutical Indu... (NYSE:TEVA)
過去 株価チャート
から 6 2024 まで 7 2024
Teva Pharmaceutical Indu... (NYSE:TEVA)
過去 株価チャート
から 7 2023 まで 7 2024